Meuldermans W E, Lauwers W F, Heykants J J
Arch Int Pharmacodyn Ther. 1976 May;221(1):140-9.
(R)-(+)-etomidate and (S)-(-)-etomidate were found to be metabolized in-vitro by various rat liver homogenization fractions: the 16,000 g supernatant fraction caused a more intensive metabolic breakdown than the microsomal fraction; the 100,000 g supernatant fraction was only slightly active. The metabolism was somewhat more rapid and more extensive for the (R)-(+)-etomidate than for the (S)-(-)-isomer. For both isomers, a dose-dependence was observed: the smaller the substrate concentration, the smaller the relative amount of unmetabolized drug, and the more the rate of metabolic breakdown after a certain incubation time slowed down. Only minor qualitative differences between the metabolic pathways of the two isomers were observed. The main metabolic pathway for the in-vitro metabolism was the hydrolysis of the ethyl ester. Decarboxylation and oxidative N-dealkylation were also observed.
研究发现,(R)-(+)-依托咪酯和(S)-(-)-依托咪酯在体外可被大鼠肝脏不同匀浆组分代谢:16,000g上清液组分引起的代谢分解比微粒体组分更强烈;100,000g上清液组分活性较弱。(R)-(+)-依托咪酯的代谢比(S)-(-)-异构体稍快且更广泛。对于两种异构体,均观察到剂量依赖性:底物浓度越小,未代谢药物的相对量越小,且在一定孵育时间后代谢分解速率减慢得越多。两种异构体的代谢途径仅存在微小的定性差异。体外代谢的主要途径是乙酯的水解。还观察到脱羧和氧化N-去烷基化。